Ascletis Pharma Inc. (HKG:1672)
Hong Kong · Delayed Price · Currency is HKD 9.79
-0.27 (-2.68%)
Sep 10, 2026, 11:56 AM HKT
Ascletis Pharma Revenue
Ascletis Pharma had revenue of 947.00K CNY in the twelve months ending June 30, 2026, down -59.94% year-over-year. In the year 2025, Ascletis Pharma had annual revenue of 2.03M with 58.07% growth.
Revenue (ttm)
947.00K CNY
Revenue Growth
-59.94%
P/S Ratio
9,719.92
Revenue / Employee
4.69K CNY
Employees
202
Market Cap
10.63B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.03M | 745.00K | 58.07% |
| Dec 31, 2024 | 1.28M | -55.31M | -97.73% |
| Dec 31, 2023 | 56.60M | 2.51M | 4.63% |
| Dec 31, 2022 | 54.09M | -22.79M | -29.64% |
| Dec 31, 2021 | 76.88M | 41.88M | 119.64% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Everest Medicines | 2.78B |
| HBM Holdings | 1.40B |
| Ascentage Pharma Group International | 741.90M |
| Alphamab Oncology | 598.06M |
| Suzhou Ribo Life Science | 536.18M |
| CStone Pharmaceuticals | 490.92M |
| Nanjing Leads Biolabs | 246.16M |
| GenFleet Therapeutics (Shanghai) | 144.96M |
Ascletis Pharma News
- 3 days ago - Ascletis Announces Inclusion in the Hong Kong Stock Connect List under the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect Programs - PRNewsWire
- 10 days ago - Ascletis Announces First Participant Dosed in a Global Phase III Clinical Program of Once-Daily Oral Small Molecule GLP-1 Receptor Agonist ASC30 for Chronic Weight Management - PRNewsWire
- 6 weeks ago - Ascletis Announces Once-Monthly Subcutaneously Administered GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, Demonstrated Superior Weight Loss in a Diet-Induced Obese Mouse Model - PRNewsWire
- 1 month ago - Ascletis Selects for Clinical Development a Fixed-Dose Combination of First-in-Class Oral Small Molecule GIPR Agonist, ASC48, and Oral Small Molecule GLP-1R Agonist, ASC30 - PRNewsWire
- 2 months ago - Ascletis Announces U.S. FDA IND Clearance for Phase I Study of Once-Monthly Subcutaneously Administered GLP-1R/GIPR Dual Peptide Agonist, ASC35, for the Treatment of Obesity - PRNewsWire
- 3 months ago - Ascletis Reinforces Its Differentiated Obesity Portfolio at American Diabetes Association (ADA) 2026 Scientific Sessions, Showcasing ASC30 Clinical Data and Exciting Preclinical Findings from ASC37 and ASC39 - PRNewsWire
- 4 months ago - Ascletis to Present Data on Multiple Programs at the 33rd European Congress on Obesity (ECO 2026) - PRNewsWire
- 4 months ago - Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions - PRNewsWire